Find a Physician | How to Contribute | Contact Us | Clinical Trials
Search: 
Select a Cancer Type:
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Clinical Trial NU 10C03

Title
Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer
Principal Investigator
Jeffrey Raizer
Details
  • Status: Accepting New Patients
  • Study Type: Therapeutic, Treatment
  • Protocol No:.NU 10C03
Purpose
The purpose of this research study is to determine a safe dose of the drug Trastuzumab and then determine how effective this treatment is.
Overview
The drug being studied is Trastuzumab, a medicine that is used to slow or stop the growth of cancerous tumors that are HER-2 positive. Patients are being asked to participate in this study because they have been diagnosed with having tumor cells in their spinal fluid. This study will investigate the safety and effects of this drug when given directly into the spinal fluid.
Eligibility
Some of the eligibility criteria include:
  • Participants must be at least 18 years of age.
  • Participants must have breast cancer that’s spread to the layers of tissue that cover the brain and the spinal cord.
  • Participants must have breast cancer that is HER2 positive.
Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Description of Treatment
Trastuzumab is an investigational drug which has not been approved by the Food and Drug Administration (FDA). Patients will be treated at one of 4 dose levels, but the dose given to each individual participant will remain the same throughout treatment. The study will begin by starting with a low dose that appears to be safe and increasing until the highest dose is met. If any one of the doses has too many side effects for participants, the rest of the participants will then be treated at the lower dose level. Prior to treatment, an Ommaya reservoir will be placed under the scalp. This device has a small catheter inserted into a fluid filled space and allows fluid to be removed and treatment to be instilled into it. Participants will remain on study as long as they are deriving benefit and are not having any bad side effects that are felt to be harmful.
Contact
Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
312.695.1102
cancertrials@northwestern.edu

Find Related Clinical Trials

Browse by Disease Sites

Other Clinical Trials by Jeffrey Raizer

last updated: 21-Oct-14 05:18 AM

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.